DB18643InvestigationalCell transplant therapies
OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.
- Also known as
- Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene
- Code names
- OTL-203
Resolves to
Compound
What you can answer from here — as of September 25, 2025
Which companies are running trials of OTL-203, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account